We are live on ! Find out more
PRVB

Provention Bio, Inc. Common Stock
PRVB

Delisted

PRVB was delisted on the 26th of April, 2023.

Back to rankings

1 hedge funds and large institutions have $2.8M invested in Provention Bio, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 180 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 182 → 1 (-181)

100% less capital invested

Capital invested by funds: $1.47B → $2.8M (-$1.47B)

100% less funds holding in top 10

Funds holding in top 10: 9 → 0 (-9)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 180

Holders
1
Holders Change
-181
Holders Change %
-99.45%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
-9
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
180
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
SC
Sessa Capital
New York
-$214M
2
BlackRock
BlackRock
New York
-$137M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$101M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$87.7M
5
PCM
Pentwater Capital Management
Florida
-$75.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
VI
26
Versor Investments
New York
– -$13.7M -570,466 Closed
Citadel Advisors
27
Citadel Advisors
Florida
– -$12.5M -520,560 Closed
Voloridge Investment Management
28
Voloridge Investment Management
Florida
– -$12M -499,080 Closed
D.E. Shaw & Co
29
D.E. Shaw & Co
New York
– -$11.8M -489,613 Closed
Janus Henderson Group
30
Janus Henderson Group
United Kingdom
– -$10.3M -429,026 Closed
Ameriprise
31
Ameriprise
Minnesota
– -$9.93M -412,127 Closed
AC
32
Armistice Capital
New York
– -$9.64M -400,000 Closed
PAI
33
Palo Alto Investors
California
– -$9.42M -390,800 Closed
Susquehanna International Group
34
Susquehanna International Group
Pennsylvania
– -$8.77M -363,758 Closed
N
35
Nuveen
North Carolina
– -$8.13M -337,165 Closed
Fidelity International
36
Fidelity International
Bermuda
– -$7.93M -329,000 Closed
UBS Group
37
UBS Group
Switzerland
– -$7.71M -320,038 Closed
CCM
38
Crabel Capital Management
California
– -$7.6M -315,391 Closed
LOAMS
39
Lombard Odier Asset Management (Switzerland)
Switzerland
– -$7.59M -314,862 Closed
Principal Financial Group
40
Principal Financial Group
Iowa
– -$7.38M -306,298 Closed
JP Morgan Chase
41
JP Morgan Chase
New York
– -$7.35M -305,059 Closed
Allianz Asset Management
42
Allianz Asset Management
Germany
– -$7.17M -297,400 Closed
WU
43
Washington University
Missouri
– -$7.02M -291,253 Closed
E
44
Ergoteles
New York
– -$6.69M -277,626 Closed
FFH
45
Fairfax Financial Holdings
Ontario, Canada
– -$6.67M -277,000 Closed
CCM
46
Chicago Capital Management
Illinois
– -$6.62M -274,515 Closed
GF
47
Gabelli Funds
New York
– -$6.55M -271,810 Closed
AR
48
Advisory Research
Illinois
– -$5.66M -235,000 Closed
Bank of New York Mellon
49
Bank of New York Mellon
New York
– -$5.43M -225,493 Closed
PMAM
50
Picton Mahoney Asset Management
Ontario, Canada
– -$5.42M -225,000 Closed
1
2
3 4 5

PRVB Hedge Fund Activity: Q2 2023 in Review

1 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Provention Bio, Inc. Common Stock (PRVB) for Q2 2023, worth a combined $2.8M — down 100% from $1.47B a quarter earlier.

Sellers outnumbered buyers: 180 funds closed out of PRVB and 0 opened new positions — a net loss of 180 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Sessa Capital, exiting entirely with an estimated $214M sold.

  • 1 institutional investor held Provention Bio, Inc. Common Stock (PRVB) as of Q2 2023, down from 182 in Q1 2023.
  • Funds reported $2.8M of Provention Bio, Inc. Common Stock stock for Q2 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Provention Bio, Inc. Common Stock positions in Q2 2023 and 180 closed out, a net change of -180 holders.
  • The largest Provention Bio, Inc. Common Stock seller in Q2 2023 was Sessa Capital, an estimated $214M sold.

Based on aggregated 13F filings for Q2 2023.